FDA Brief

Warning letters Food

FDA warning letter to

Osmosis, LLC

High riskIssued Aug 23, 2023Posted Sep 5, 2023Division of Human and Animal Food Operations East IV

Osmosis sold unapproved drug products with disease claims and had dietary supplement CGMP and labeling violations.

What happened

FDA inspected Osmosis's Evergreen, CO facility from January 5, 2023, through January 13, 2023, and later reviewed product labels and the website. FDA found the products were intended as drugs because of claims to treat eczema, psoriasis, rosacea, diabetes, and high cholesterol, without drug approval or adequate directions. The inspection also found dietary supplement current good manufacturing practice (CGMP) violations and labeling violations.

What FDA found

  1. The products were unapproved new drugs because they were intended to treat diseases such as eczema, psoriasis, rosacea, and diabetes.

    section 201(p) and 505(a) of the Act [21 U.S.C. 321(p), 355(a)]
  2. The products lacked adequate directions for use because they were intended for diseases not suitable for self-treatment without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]
  3. The firm had no written quality control procedures, including for material review and disposition decisions.

    21 CFR 111.103
  4. The firm lacked written procedures and records for cleaning and sanitizing equipment, including the dust-removal equipment.

    21 CFR 111.25(c), 111.27(d), and 111.35(a)
  5. The firm had no written procedures for reviewing and investigating product complaints.

    21 CFR 111.553 and 111.560
  6. Several supplement labels lacked a domestic address or phone number for receiving serious adverse event reports.

    section 403(y) of the Act [21 U.S.C. 343(y)]

What FDA wants

FDA asks Osmosis to notify it in writing within 15 working days of the specific steps taken to address the violations, including steps to prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, FDA asks for the reason and the expected completion time.

Who should pay attention

  • dietary supplement brands that make disease-type claims
  • contract manufacturers and labelers of liquid supplements
  • retailers and online platforms selling supplement products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk